Elan’s Tysabri ‘can improve cognitive function in MS patients’

Tysabri, the treatment for multiple sclerosis (MS) developed by Elan and Biogen Idec, can “significantly” reduce the worsening of cognitive function in MS patients, according to new trial data.

Elan, the Irish pharmaceutical manufacturer, claims that cognitive function is an under-recognised symptom of MS, despite the fact that between 43 and 65 per cent of MS patients demonstrate a “measurable” impairment in cognitive ability – something that can occur from the early stages of the disease, with only mild physical disability.

The study, entitled Affirm, included 942 patients and revealed that Tysabri reduced the level of cognitive dysfunction in MS patients by 43 per cent, in comparison to the placebo.

Richard Rudick, director of the Mellen Centre for MS treatment and research at the Cleveland Clinic, stated: “The important positive effects of Tysabri on cognitive functioning and quality of life add to the important benefits already reported on progression of disability and relapses.”

He added that the Affirm study provides “strong evidence” that the neurological benefits of Tysabri use are perceived as “important improvements” by patients.

Tysabri, developed and manufactured in conjunction with Biogen Idec, was temporarily withdrawn following concerns that a small number of users developed progressive multifocal leukoencephalopathy, a rare infection that is normally debilitating or fatal.

Consequently, the drug is indicated for use in patients with high disease activity, despite beta-interferon treatment.